Autolus Therapeutics (AUTL) Interest Expenses (2021 - 2025)

Autolus Therapeutics (AUTL) has 5 years of Interest Expenses data on file, last reported at $22.8 million in Q4 2025.

• For the quarter ending Q4 2025, Interest Expenses rose 174.06% year-over-year to $22.8 million; the trailing twelve-month figure through Dec 2025 stood at $36.7 million (up 294.56% YoY), and the FY2025 full-year result was $36.7 million, up 294.56% from the prior year.
• Interest Expenses for Q4 2025 stood at $22.8 million, up from $10.5 million in the prior quarter.
• Across five years, Interest Expenses topped out at $30.1 million in Q4 2023 and bottomed at -$30.8 million in Q4 2024.
• The 5-year median for Interest Expenses is $5.0 million (2023), against an average of $5.9 million.
• The widest annual swing landed in 2023, when Interest Expenses jumped 771.51%; it then slumped 202.35% in 2024.
• A 5-year view of Interest Expenses shows it stood at $1.1 million in 2021, then jumped by 212.85% to $3.5 million in 2022, then surged by 771.51% to $30.1 million in 2023, then plunged by 202.35% to -$30.8 million in 2024, then surged by 174.06% to $22.8 million in 2025.
• The last three Interest Expenses figures came in at $22.8 million (Q4 2025), $10.5 million (Q3 2025), and -$6.8 million (Q2 2025), per Business Quant data.

Peer Comparison